Comprehensive genomic profiling (CGP) by next-generation sequencing (NGS) is a powerful clinical tool for assessing a patient’s tumor mutational profile, identifying the most appropriate treatment strategy and individualizing each patient’s cancer care.

While genomic testing has historically been limited to a handful of centralized commercial laboratories — thus reducing patient access and increasing turnaround times for clinical results — the PGDx elio™ tissue complete test offers an FDA-cleared solution, including automated bioinformatics analysis for tumor profiling in-house.

At the 2022 Cancer Genomics Consortium, Ravindra Kolhe, MD, PhD, FACP, of Augusta University, discussed the critical role of CGP in precision oncology, in-house versus send-out testing approaches, challenges in implementation, the path to reimbursement and more.